Although most of the NSCLC patients in our cohort harbored only one pathogenic ATM/ATR mutation, the additional FA/HR mutations could further weaken the DDR pathways, making them vulnerable to further DDR inhibition. Here, ATR is linked to non-small cell lung carcinoma.